Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- LivDerm
- TME
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
$0.00
Hidradenitis suppurativa (HS), also called acne inversa, is an inflammatory disease characterized by recurring, painful abscesses, and fistulous tracts, and can impact adults and pediatric patients. Symptoms of HS include pain and scarring as well as psychological consequences, such as embarrassment, social isolation, and depression, and is associated with a poor quality of life. Several studies suggest that the prevalence of HS ranges from 0.00033 to 4.1%, although underdiagnosis or improper diagnosis is an issue.
- LivDerm
- TME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development and FDA-approval of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Moreover, these vital healthcare providers need education on disease pathophysiology, burden, and the impact this illness imparts on the whole patient.
- CMHC
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
$0.00
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with heart failure. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), and despite a higher HF symptom burden, they are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF have been made, all with the potential to alter treatment paradigms now and in the future.
- CMHC
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
$0.00
Atrial fibrillation (AF) remains underdiagnosed, particularly in African American patients with a high burden of AF risk factors, such as those with cardiometabolic comorbidities. Additionally, stroke prevention in these patients is suboptimal, with suboptimal application of evidence-based therapies and guidelines, including the suboptimal use of direct oral anticoagulants (DOACs).
- LivDerm
- TME
- 2.00 AAPA Category I CME
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC
- 2.00 Participation
$0.00
The ever-increasing impact of dermatologic conditions continues to be a major challenge for dermatologists and other health care providers in the United States (US). Dermatology practitioners diagnose and treat more than 3000 diseases across the age spectrum. Therefore, clinicians are challenged to remain current in their knowledge and competence in the diagnosis and management of cutaneous disease.
- CMHC
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), Additionally, the impact of commonly-used medications with high sodium content contributes to this burden. As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including in patients with sleep disorders, as well as practical strategies to minimize the impact of elevated sodium.
- LivDerm
- TME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Psoriasis is a difficult disease to manage due to a variety of factors including fluctuations in disease severity, limited treatment options, and a limited understanding of the pathogenesis of disease. Recently, the first new topical for PsO since 1997 was approved for adults with plaque PsO. This agent is a novel, steroid-free aryl hydrocarbon receptor (AhR) agonist with no restrictions for duration, location, or extent of use.
- CMHC
- 2.25 ACPE Pharmacy
- 2.25 AMA PRA Category 1 Credit™
- 2.25 ANCC
- 2.25 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), including in the development of hypertension and risk of adverse cardiovascular outcomes. Additionally, the impact of commonly-used medications with high sodium content contributes to this burden. As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including patients with insufficient or impaired sleep, as well as practical strategies to minimize the impact of elevated sodium.
- CMHC
- 1.75 ACPE Pharmacy
- 1.75 AMA PRA Category 1 Credit™
- 1.75 ANCC
- 1.75 Participation
$0.00
Idiopathic hypersomnia (IH) is a chronic neurological disorder that has significant impacts on daily functioning, with symptoms that include, but often go beyond excessive daytime sleepiness (EDS). Overall awareness about IH remains low, which contributes to the suboptimal recognition of this condition, which is often exacerbated by insufficient diagnostic criteria leading to delayed diagnosis and treatment.
Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
- CMHC
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
$0.00
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors.